NCT06632236View on ClinicalTrials.gov

5G-EMERALD: Amivantamab in Malignant Brain Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

March 5, 2026

Study Completion Date

March 5, 2027

Conditions
Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)Diffuse Hemispheric Glioma, H3 G34-MutantGlioblastoma Multiforme (GBM)
Interventions
DRUG

Amivantamab

Amivantamab will be supplied in single-use 350 mg injectable solution, provided as a 7 ml per glass vial (50mg/ml), intended for IV infusion.

Trial Locations (2)

CB2 0QQ

RECRUITING

Cambridge University Hospitals, Cambridge

SM2 5PT

RECRUITING

The Royal Marsden Hospital - Drug Development Unit, Sutton

Sponsors
All Listed Sponsors
collaborator

Royal Marsden NHS Foundation Trust

OTHER

collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

collaborator

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

collaborator

Cancer Research UK

OTHER

collaborator

Minderoo Foundation

UNKNOWN

collaborator

University of Cambridge

OTHER

lead

Institute of Cancer Research, United Kingdom

OTHER